We are pleased to have partnered with Pfizer to launch the Do You C Us? Campaign.
The Do You C Us? Campaign aims to raise awareness of the issues faced by people living with rare and less common cancers.
The Parliamentary launch event took place at 2pm on 29th June 2021. Paul Bristow MP chaired and other speakers included Jane Lyons (Cancer52 CEO), Dr Ellie Cannon and Bob (who is living with a rare or less common cancer).
We have three key asks for this campaign:
In the NHS Long Term Plan, the NHS committed to diagnosing 75% of all cancers at stage 1 or 2 by 2028. In order to meet this target, improvements are required across all cancers – including rare and less common cancers.
Work should be undertaken to identify people 'missing' from the system, including people with rare and less common cancers. People must be reassured that it is safe to come forward for treatment.
Cancer must remain a Government priority. Cancer services and the cancer workforce, including those for people with rare and less common cancers, should receive sufficient investment and funding for the future. This must be set out in the next Comprehensive Spending Review.
Visit the campaign website www.DoYouCUs.org.uk to find out more.
Thanks to the people living with rare and less common cancers who shared their stories for the campaign and to Cancer52 members for their support.